Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases

PURPOSE: Brain metastases can occur in up to 50% of patients with metastatic HER2-positive breast cancer. Because patients with active brain metastases were excluded from previous pivotal clinical trials, the central nervous system (CNS) activity of the antibody–drug conjugate trastuzumab deruxtecan...

Descripción completa

Detalles Bibliográficos
Autores principales: Kabraji, Sheheryar, Ni, Jing, Sammons, Sarah, Li, Tianyu, Van Swearingen, Amanda E.D., Wang, Yanzhi, Pereslete, Alyssa, Hsu, Liangge, DiPiro, Pamela J., Lascola, Chris, Moore, Heather, Hughes, Melissa, Raghavendra, Akshara S., Gule-Monroe, Maria, Murthy, Rashmi K., Winer, Eric P., Anders, Carey K., Zhao, Jean J., Lin, Nancy U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811155/
https://www.ncbi.nlm.nih.gov/pubmed/36074155
http://dx.doi.org/10.1158/1078-0432.CCR-22-1138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811155/
https://www.ncbi.nlm.nih.gov/pubmed/36074155
http://dx.doi.org/10.1158/1078-0432.CCR-22-1138

Ejemplares similares